Brian C Vanderplas

US Patent:

6403776, Jun 11, 2002

Filed:

Jul 5, 2000

Appl. No.:

09/610057

Inventors:

David H. B. Ripin - Westbrook CT
Brian C. Vanderplas - Old Lyme CT
Takushi Kaneko - Guilford CT
William T. McMillen - Fisher IN
Robert W. McLaughlin - Groton CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07H 100

US Classification:

536 74, 536 185

Abstract:

The invention relates to a method of preparing a macrolide antibiotic of the formula wherein R , R , R , R , R are defined above. These antibiotics are useful as antibacterial and antiprotozoal agents in mammals, including man, as well as in fish and birds. The invention also includes novel compounds made by the preparation of the macrolide antibiotic.

US Patent:

7129263, Oct 31, 2006

Filed:

Oct 15, 2004

Appl. No.:

10/966712

Inventors:

Stanton Furst McHardy - Coventry RI, US
John Anthony Ragan - Gales Ferry CT, US
Derek Lawrence Tickner - Waterford CT, US
Brian Clement Vanderplas - Old Lyme CT, US
Jotham Wadsworth Coe - Niantic CT, US

International Classification:

A61K 31/403
C07D 209/52

US Classification:

514412, 548515

Abstract:

This present invention relates to a new and improved reductive amination process for the preparation of 3-azabicyclo[3. 1. 0]hexane derivatives and pharmaceutical compositions comprising such derivatives. The invention particularly relates to using such derivatives to treat certain disorders and conditions, including, for example, irritable bowel syndrome, drug addiction or dependency, alcohol addiction or dependency, depression, and eating disorders.

US Patent:

60311142, Feb 29, 2000

Filed:

Aug 16, 1999

Appl. No.:

9/374869

Inventors:

Keith M. DeVries - Chester CT
Brian C. Vanderplas - Old Lyme CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D20712

US Classification:

548556

Abstract:

A method for preparing hydroxamic acid derivatives which are useful as analgesic, antiinflammatory, or neuroprotective agents.

US Patent:

60909420, Jul 18, 2000

Filed:

Sep 29, 1999

Appl. No.:

9/408998

Inventors:

Keith M. DeVries - Chester CT
Jeffrey W. Raggon - Uncasville CT
Ravi M. Shanker - Groton CT
Frank J. Urban - Waterford CT
Brian C. Vanderplas - Old Lyme CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07F 702
C07D40512
C07D40312

US Classification:

546 14

Abstract:

The instant invention relates to intermediates of Formula II, ##STR1## wherein R. sup. 1, R. sup. 2 and R. sup. 3 are as defined in the specification, and to processes for preparing such intermediates. This invention also relates to processes for preparing compounds of Formula III, ##STR2## and enantiomers thereof, wherein R. sup. 2, R. sup. 3 and R. sup. 4 are as defined in the specification. Compounds of Formula II and Formula III are intermediates in the preparation of a potent. beta. sub. 3 adrenergic receptor agonist. The instant invention also relates to processes for preparing the. beta. sub. 3 adrenergic receptor agonist using the compounds of Formula II and Formula III.

US Patent:

54553504, Oct 3, 1995

Filed:

Oct 13, 1993

Appl. No.:

8/137049

Inventors:

Dennis M. Godek - Glastonbury CT
Charles W. Murtiashaw - North Stonington CT
Frank J. Urban - Waterford CT
Brian C. Vanderplas - Niantic CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D47104
C07D22700

US Classification:

544349

Abstract:

(C. sub. 1 -C. sub. 3)Alkyl-4,6,7,8,9,9a-hexahydro-2H,3H-pyrido[1,2-a]pyrazin-1-one-7-c arboxylate esters, important precursors to certain bis-aza-bicyclic anxiolytics, can be prepared from di(C. sub. 1 -C. sub. 3)alkyl cis-piperidine-2,5-dicarboxylate starting material by a new process via a new class of intermediates, di(C. sub. 1 -C. sub. 3)alkyl cis-N-(2-(phthalimido)ethyl)piperidine-2,5-dicarboxylates. In the process, the starting material is reacted with either 2-(phthalimido)ethyl triflate or 2-(phthalimido)acetaldehyde to form the new intermediate, which can then be cyclized to the aforementioned precursor.

US Patent:

51854490, Feb 9, 1993

Filed:

Feb 27, 1991

Appl. No.:

7/661730

Inventors:

Dennis M. Godek - Glastonbury CT
Charles W. Murtiashaw - North Stonington CT
Frank J. Urban - Waterford CT
Brian C. Vanderplas - Niantic CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D227093
C07D47104

US Classification:

546272

Abstract:

(C. sub. 1 -C. sub. 3)Alkyl-4,6,7,8,9,9a-hexahydro-2H,3H-pyrido-[1,2-a]pyrazin-1-one-7- carboxylate esters, important precursors to certain bis-aza-bicyclic anxiolytics, can be prepared from di(C. sub. 1 -C. sub. 3)alkyl cis-piperidine-2,5-dicarboxylate starting material by a new process via a new class of intermediates, di(C. sub. 1 -C. sub. 3)alkyl cis-N-(2-(phthalimido)ethyl)piperidine-2,5-dicarboxylates. In the process, the starting material is reacted with either 2-(phthalimido)ethyl triflate or 2-(phthalimido)acetaldehyde to form the new intermediate, which can then be cyclized to the aforementioned precursor.

US Patent:

61244570, Sep 26, 2000

Filed:

Jan 20, 2000

Appl. No.:

9/488245

Inventors:

Keith M. DeVries - Chester CT
Jeffrey W. Raggon - Uncasville CT
Ravi M. Shanker - Groton CT
Frank J. Urban - Waterford CT
Brian C. Vanderplas - Old Lyme CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07F 702
C07D40502
C07D21174
C07D21353

US Classification:

546 14

Abstract:

The instant invention relates to intermediates of Formula II, ##STR1## wherein R. sup. 1, R. sup. 2 and R. sup. 3 are as defined in the specification, and to processes for preparing such intermediates. This invention also relates to processes for preparing compounds of Formula III, ##STR2## and enantiomers thereof, wherein R. sup. 2, R. sup. 3 and R. sup. 4 are as defined in the specification. Compounds of Formula II and Formula III are intermediates in the preparation of a potent. beta. sub. 3 adrenergic receptor agonist. The instant invention also relates to processes for preparing the. beta. sub. 3 adrenergic receptor agonist using the compounds of Formula II and Formula III.